International Journal of Clinical Oncology

, Volume 10, Issue 6, pp 405–410

Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer

  • Hiroji Uemura
  • Hisashi Hasumi
  • Takashi Kawahara
  • Shinpei Sugiura
  • Yasuhide Miyoshi
  • Noboru Nakaigawa
  • Jun-ichi Teranishi
  • Kazumi Noguchi
  • Hitoshi Ishiguro
  • Yoshinobu Kubota
ORIGINAL ARTICLE

DOI: 10.1007/s10147-005-0520-y

Cite this article as:
Uemura, H., Hasumi, H., Kawahara, T. et al. Int J Clin Oncol (2005) 10: 405. doi:10.1007/s10147-005-0520-y

Abstract

Background

We previously demonstrated that an angiotensin II receptor blocker (ARB) had the potential to inhibit cell proliferation of prostate cancer. In this study, we examined whether an ARB could elicit an antiproliferative effect on hormone-refractory prostate cancer, clinically.

Methods

Twenty-three patients with advanced hormone-refractory prostate cancer who had already received secondary hormonal therapy using dexamethasone, and who were no longer receiving conventional therapy, were enrolled. All of the patients received candesartan 8 mg once daily per os and, simultaneously, androgen ablation. Change in prostate-specific antigen (PSA) was determined as the primary endpoint. The secondary end-point was change in performance status (PS). To investigate angiotensin II type 1 (AT1) receptor expression in prostate cancer tissue, real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was performed, using specimens, from untreated patients with prostate cancer.

Results

Eight patients (34.8%) showed responsive PSA changes; six showed a decrease immediately after starting administration and two showed a stable level of PSA. Six men with a PSA decline of more than 50% showed an improvement in PS. The mean time to PSA progression (TTPP) in responders was 8.3 months (range, 1–24 months). Half of the patients showed stable or improved PS during treatment. With regard to toxic effects, only one patient showed hypotension during treatment. The RT-PCR showed that AT1 receptor expression in well-differentiated adenocarcinoma was higher than that in poorly differentiated adenocarcinoma.

Conclusion

These data showed that an ARB had potential biological effects on prostate cancer, suggesting the usefulness of the cytostatic activity of such agents on recurrent prostate cancer.

Key words

Angiotensin II receptor blockerHormone-refractory prostate cancerProstate-specific antigen

Copyright information

© The Japan Society of Clinical Oncology 2005

Authors and Affiliations

  • Hiroji Uemura
    • 1
  • Hisashi Hasumi
    • 1
  • Takashi Kawahara
    • 1
  • Shinpei Sugiura
    • 1
  • Yasuhide Miyoshi
    • 1
  • Noboru Nakaigawa
    • 1
  • Jun-ichi Teranishi
    • 2
  • Kazumi Noguchi
    • 2
  • Hitoshi Ishiguro
    • 1
  • Yoshinobu Kubota
    • 1
  1. 1.Department of UrologyYokohama City University Graduate School of MedicineYokoyamaJapan
  2. 2.Department of UrologyYokohama City University Medical CenterYokohamaJapan